Print

Active Biotech AB Interim Report January - June 2013

2013-08-07

Events during January - June 2013:

Laquinimod
·positive results from Phase IIa study of laquinimod in active lupus nephritis
·Teva plans continued clinical development of laquinimod for the treatment of lupus nephritis
·data presented at AAN showed a slower disability progression for multiple sclerosis patients who commenced early treatment with laquinimod compared with delayed treatment

Tasquinimod
·analysis plan for Phase III trial updated; primary PFS analysis expected at the same time as first interim overall survival analysis in 2014
·Phase II follow-up study shows an impact of tasquinimod on bone metastases as measured by
Bone Scan Index (BSI); results presented at ASCO

ANYARA
·improved overall survival in a subgroup of renal cell cancer patients in the Phase II/III study; results presented at ASCO

57-57 (paquinimod)
·clinical trial in systemic sclerosis concluded, evaluation under way

ISI
·patent applications filed

Jan - Jun Jan - Dec
(MSEK) 2013 2012 2012
  • Net sales
5.0 96.6 227.9
  • Operating loss
-156.5 -120.6 -163.2
  • Net loss
-159.2 -123.5 -175.0
  • Earnings per share (SEK)
-2.18 -1.79 -2.54
  • Cash and cash equivalents (MSEK)
389.1 383.7 216.7

For further information, please contact:

Tomas Leanderson, President and CEO
Tel: +46 (0)46-19 20 95

Hans Kolam, CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB(Corp. Reg. No. 556223-9227)
Box 724, SE- 220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com


pdfActive Biotech AB Interim Report January - June 2013



Back